Therapeutic targeting of the angiopoietin-TIE pathway

Nature Reviews Drug Discovery

Volumn 16, Issue 9, 2017, Pages 635-661

  Saharinen, Pipsa ^a   Eklund, Lauri ^b   Alitalo, Kari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; TIE 1 RECEPTOR; TIE RECEPTOR; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; CAVERNOUS HEMANGIOMA; DIABETIC ANGIOPATHY; DRUG TARGETING; EYE DISEASE; HUMAN; INFECTION; INFLAMMATION; INTRACELLULAR SIGNALING; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PROCEDURES; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, TIE; SIGNAL TRANSDUCTION; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85028701474     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.278     Document Type: Review

References (313)

1. Welti, J., Loges, S., Dimmeler, S. & Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200 (2013).
2. Campochiaro, P. A. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 49, 67-81 (2015).
3. Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385-403 (2016).
4. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
5. Augustin, H. G., Koh, G. Y., Thurston, G. & Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10, 165-177 (2009).
6. Thurston, G. & Daly, C. The complex role of angiopoietin-2 in the angiopoietin-Tie signaling pathway. Cold Spring Harb. Perspect. Med. 2, a006550 (2012).
7. Eklund, L. & Saharinen, P. Angiopoietin signaling in the vasculature. Exp. Cell Res. 319, 1271-1280 (2013).
8. Saharinen, P., Eklund, L., Pulkki, K., Bono, P. & Alitalo, K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 17, 347-362 (2011).
9. Partanen, J. et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol. 12, 1698-1707 (1992).
10. Dumont, D. J., Yamaguchi, T. P., Conlon, R. A., Rossant, J. & Breitman, M. L. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7, 1471-1480 (1992).
11. Batard, P. et al. The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. Blood 87, 2212-2220 (1996).
12. Hashiyama, M. et al. Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells. Blood 87, 93-101 (1996).
13. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
14. Abou-Khalil, R. et al. Autocrine and paracrine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-renewal. Cell Stem Cell 5, 298-309 (2009).
15. Ito, K. et al. Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. Science 354, 1156-1160 (2016).
16. Saharinen, P. et al. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J. Cell Biol. 169, 239-243 (2005).
17. Fukuhara, S. et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol. 10, 513-526 (2008).
18. Saharinen, P. et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell Biol. 10, 527-537 (2008).
19. Korhonen, E. A. et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J. Clin. Invest. 126, 3495-3510 (2016).
20. Savant, S. et al. The orphan receptor Tie1 controls angiogenesis and vascular remodeling by differentially regulating Tie2 in tip and stalk cells. Cell Rep. 12, 1761-1773 (2015).
21. D'Amico, G. et al. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J. Clin. Invest. 124, 824-834 (2014).
22. Koh, G. Y. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol. Med. 19, 31-39 (2013).
23. Kim, I. et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Circ. Res. 86, 24-29 (2000).
24. Kontos, C. D., Cha, E. H., York, J. D. & Peters, K. G. The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol. Cell. Biol. 22, 1704-1713 (2002).
25. Daly, C. et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 18, 1060-1071 (2004).
26. Wilhelm, K. et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature 529, 216-220 (2016).
27. Thurston, G. et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511-2514 (1999).
28. Limaye, N. et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat. Genet. 41, 118-124 (2009).
29. Limaye, N. et al. Somatic activating PIK3CA mutations cause venous malformation. Am. J. Hum. Genet. 97, 914-921 (2015).
30. Castel, P. et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci. Transl Med. 8, 332-342 (2016).
31. Castillo, S. D. et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. Sci. Transl Med. 8, 332-343 (2016).
32. Aspelund, A. et al. The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. J. Clin. Invest. 124, 3975-3986 (2014).
33. Thomson, B. R. et al. A lymphatic defect causes ocular hypertension and glaucoma in mice. J. Clin. Invest. 124, 4320-4324 (2014).
34. Souma, T. et al. Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity. J. Clin. Invest. 126, 2575-2587 (2016).
35. Gamble, J. R. et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ. Res. 87, 603-607 (2000).
36. David, S., Ghosh, C. C., Mukherjee, A. & Parikh, S. M. Angiopoietin-1 requires IQ domain GTPase-activating protein 1 to activate Rac1 and promote endothelial barrier defense. Arterioscler. Thromb. Vasc. Biol. 31, 2643-2652 (2011).
37. Gavard, J., Patel, V. & Gutkind, J. S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev. Cell 14, 25-36 (2008).
38. Frye, M. et al. Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie 2 in the absence of VE cadherin. J. Exp. Med. (2015).
39. Fiedler, U. et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103, 4150-4156 (2004).
40. Maisonpierre, P. C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997).
41. Mandriota, S. J. & Pepper, M. S. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ. Res. 83, 852-859 (1998).
42. Oh, H. et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J. Biol. Chem. 274, 15732-15739 (1999).
43. Simon, M. P., Tournaire, R. & Pouyssegur, J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J. Cell. Physiol. 217, 809-818 (2008).
44. Choi, H. J. et al. Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2. Nat. Commun. 6, 6943 (2015).
45. Ghosh, C. C. et al. Drug repurposing screen identifies Foxo1-dependent angiopoietin-2 regulation in sepsis. Crit. Care Med. 43, e230-e240 (2015).
46. Fiedler, U. et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat. Med. 12, 235-239 (2006).
47. Parikh, S. M. et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PloS Med. 3, e46 (2006).
48. Hakanpaa, L. et al. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat. Commun. 6, 5962 (2015).
49. Kim, M. et al. Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J. Clin. Invest. 126, 3511-3525 (2016).
50. Daly, C. et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 73, 108-118 (2013).
51. Gale, N. W. et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3, 411-423 (2002).
52. Cascone, I., Napione, L., Maniero, F., Serini, G. & Bussolino, F. Stable interaction between α5β1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J. Cell Biol. 170, 993-1004 (2005).
53. Dalton, A. C., Shlamkovitch, T., Papo, N. & Barton, W. A. Constitutive association of Tie1 and Tie2 with endothelial integrins is functionally modulated by angiopoietin-1 and fibronectin. PloS ONE 11, e0163732 (2016).
54. Lee, J. et al. Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy. Sci. Transl Med. 5, 203-127 (2013).
55. Lee, H. S. et al. Gln-362 of angiopoietin-2 mediates migration of tumor and endothelial cells through association with α5β1 integrin. J. Biol. Chem. 289, 31330-31340 (2014).
56. Park, S. W. et al. Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy. Diabetes 63, 3057-3068 (2014).
57. Felcht, M. et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest. 122, 1991-2005 (2012).
58. Sfiligoi, C. et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J. Cancer 103, 466-474 (2003).
59. Helfrich, I. et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 15, 1384-1392 (2009).
60. Goede, V. et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br. J. Cancer 103, 1407-1414 (2010).
61. Wang, X. et al. The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol. 7, 188-195 (2014).
62. Scholz, A. et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 8, 35-57 (2015).
63. Rautiola, J. et al. Association of angiopoietin-2 and Ki-67 expression with vascular density and sunitinib response in metastatic renal cell carcinoma. PLoS ONE 11, e0153745 (2016).
64. Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999).
65. Oliner, J. et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516 (2004).
66. Holopainen, T. et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl Cancer Inst. 104, 461-475 (2012).
67. Hashizume, H. et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70, 2213-2223 (2010).
68. Kienast, Y. et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 19, 6730-6740 (2013).
69. Srivastava, K. et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26, 880-895 (2014).
70. Falcon, B. L. et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol. 175, 2159-2170 (2009).
71. Coxon, A. et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol. Cancer Ther. 9, 2641-2651 (2010).
72. Thurston, G. et al. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132, 3317-3326 (2005).
73. Kim, K. E. et al. In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin. Arterioscler. Thromb. Vasc. Biol. 27, 564-570 (2007).
74. Tammela, T. et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 105, 4642-4648, (2005).
75. Morisada, T. et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 105, 4649-4656 (2005).
76. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
77. Keskin, D. et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep. 10, 1066-1081 (2015).
78. Rigamonti, N. et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 8, 696-706 (2014).
79. Kloepper, J. et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl Acad. Sci. USA 113, 4476-4481 (2016).
80. Peterson, T. E. et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc. Natl Acad. Sci. USA 113, 4470-4475 (2016).
81. Shen, J. et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J. Clin. Invest. 124, 4564-4576 (2014).
82. Goel, S. et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J. Natl Cancer Inst. 105, 1188-1201 (2013).
83. Behjati, S. et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat. Genet. 46, 376-379 (2014).
84. Murali, R. et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 6, 36041-36052 (2015).
85. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
86. Rohan, T. E. et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J. Natl Cancer Inst. 106, dju136 (2014).
87. Harney, A. S. et al. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 5, 932-943 (2015).
88. Chen, L. et al. Tie2 expression on macrophages is required for blood vessel reconstruction and tumor relapse after chemotherapy. Cancer Res. 76, 6828-6838 (2016).
89. Minami, T. et al. The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep. 4, 709-723 (2013).
90. Mazzieri, R. et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512-526 (2011).
91. Im, J. H. et al. G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency. Int. J. Cancer 132, 315-326 (2013).
92. Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6, 460-463 (2000).
93. Baffert, F., Le, T., Thurston, G. & McDonald, D. M. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am. J. Physiol. Heart Circ. Physiol. 290, H107-H118 (2006).
94. Benest, A. V. et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS ONE 8, e70459 (2013).
95. Daly, C. et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc. Natl Acad. Sci. USA 103, 15491-15496 (2006).
96. Jeansson, M. et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Invest. 121, 2278-2289 (2011).
97. Hayashi, M. et al. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat. Commun. 4, 1672 (2013).
98. Tabruyn, S. P. et al. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am. J. Pathol. 177, 3233-3243 (2010).
99. David, S. et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis. Crit. Care Med. 40, 3034-3041 (2012).
100. Parikh, S. M. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS. Virulence 4, 517-524 (2013).
101. Yuan, H. T., Khankin, E. V., Karumanchi, S. A. & Parikh, S. M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol. Cell. Biol. 29, 2011-2022 (2009).
102. Singh, H., Hansen, T. M., Patel, N. & Brindle, N. P. The molecular balance between receptor tyrosine kinases Tie1 and Tie2 is dynamically controlled by VEGF and TNFα and regulates angiopoietin signalling. PLoS ONE 7, e29319 (2012).
103. David, S. et al. Acute administration of recombinant angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine 55, 251-259 (2011).
104. Ziegler, T. et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J. Clin. Invest. 123, 3436-3445 (2013).
105. Stiehl, T. et al. Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit. Care Med. 42, e654-e662 (2014).
106. Han, S. et al. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci. Transl Med. 8, 335-355 (2016).
107. Mofarrahi, M. et al. Regulation of angiopoietin expression by bacterial lipopolysaccharide. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L955-L963 (2008).
108. Kurniati, N. F. et al. The flow dependency of Tie2 expression in endotoxemia. Intensive Care Med. 39, 1262-1271 (2013).
109. Ghosh, C. C. et al. Gene control of tyrosine kinase TIE2 and vascular manifestations of infections. Proc. Natl Acad. Sci. USA 113, 2472-2477 (2016).
110. Rasmussen, A. L. et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346, 987-991 (2014).
111. Le, C. T. et al. Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-α in suppressing remodeling of blood vessels and lymphatics in airway inflammation. Am. J. Pathol. 185, 2949-2968 (2015).
112. Yuen, D. et al. Role of angiopoietin-2 in corneal lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 55, 3320-3327 (2014).
113. Suri, C. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 282, 468-471 (1998).
114. Cho, C. H. et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ. Res. 97, 86-94 (2005).
115. Syrjala, S. O. et al. Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. Am. J. Transplant 14, 1096-1108 (2014).
116. Molnar, M. Z. et al. Circulating angiopoietin-2 levels predict mortality in kidney transplant recipients: a 4-year prospective case-cohort study. Transpl. Int. 27, 541-552 (2014).
117. Nykanen, A. I. et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107, 1308-1314 (2003).
118. Syrjala, S. O. et al. Donor heart treatment with COMP-Ang1 limits ischemia-reperfusion injury and rejection of cardiac allografts. Am. J. Transplant 15, 2075-2084 (2015).
119. Tabas, I., Garcia-Cardena, G. & Owens, G. K. Recent insights into the cellular biology of atherosclerosis. J. Cell Biol. 209, 13-22 (2015).
120. Porat, R. M. et al. Specific induction of tie1 promoter by disturbed flow in atherosclerosis-prone vascular niches and flow-obstructing pathologies. Circ. Res. 94, 394-401 (2004).
121. Tressel, S. L., Huang, R. P., Tomsen, N. & Jo, H. Laminar shear inhibits tubule formation and migration of endothelial cells by an angiopoietin-2 dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 27, 2150-2156 (2007).
122. Chen-Konak, L. et al. Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells. FASEB J. 17, 2121-2123 (2003).
123. Woo, K. V. et al. Tie1 attenuation reduces murine atherosclerosis in a dose-dependent and shear stress-specific manner. J. Clin. Invest. 121, 1624-1635 (2011).
124. Theelen, T. L. et al. Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis 241, 297-304 (2015).
125. Zhou, H. J. et al. Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation. Nat. Med. 22, 1033-1042 (2016).
126. Bartlett, C. S., Jeansson, M. & Quaggin, S. E. Vascular growth factors and glomerular disease. Annu. Rev. Physiol. 78, 437-461 (2016).
127. Singh, H., Brindle, N. P. & Zammit, V. A. High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. Microvasc. Res. 79, 121-127 (2010).
128. Dessapt-Baradez, C. et al. Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J. Am. Soc. Nephrol. 25, 33-42 (2014).
129. Lee, S. et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol. Dial Transplant 22, 396-408 (2007).
130. Prenner, S. B. & Chirinos, J. A. Arterial stiffness in diabetes mellitus. Atherosclerosis 238, 370-379 (2015).
131. David, S. et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol. Dial Transplant 27, 1867-1872 (2012).
132. Chang, F. C. et al. Angiopoietin-2-induced arterial stiffness in CKD. J. Am. Soc. Nephrol. 25, 1198-1209 (2014).
133. Cho, C. H. et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc. Natl Acad. Sci. USA 103, 4946-4951 (2006).
134. Bitto, A. et al. Angiopoietin-1 gene transfer improves impaired wound healing in genetically diabetic mice without increasing VEGF expression. Clin. Sci. (Lond.) 114, 707-718 (2008).
135. Kosacka, J. et al. COMP-angiopoietin-1 recovers molecular biomarkers of neuropathy and improves vascularisation in sciatic nerve of ob/ob mice. PLoS ONE 7, e32881 (2012).
136. Hackett, S. F., Wiegand, S., Yancopoulos, G. & Campochiaro, P. A. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell. Physiol. 192, 182-187 (2002).
137. Hackett, S. F. et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J. Cell. Physiol. 184, 275-284 (2000).
138. Oshima, Y. et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J. Cell. Physiol. 199, 412-417 (2004).
139. Oshima, Y. et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J. 19, 963-965 (2005).
140. Nambu, H. et al. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J. Cell. Physiol. 204, 227-235 (2005).
141. Lux, A., Llacer, H., Heussen, F. M. & Joussen, A. M. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br. J. Ophthalmol. 91, 1318-1322 (2007).
142. Fong, D. S., Custis, P., Howes, J. & Hsu, J. W. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 117, 298-302 (2010).
143. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
144. Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006).
145. Okabe, K. et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell 159, 584-596 (2014).
146. Lee, J. et al. Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest. Ophthalmol. Vis. Sci. 55, 2191-2199 (2014).
147. Costa, P. Z. & Soares, R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 92, 1037-1045 (2013).
148. Tuuminen, R., Haukka, J. & Loukovaara, S. Poor glycemic control associates with high intravitreal angiopoietin-2 levels in patients with diabetic retinopathy. Acta Ophthalmol. 93, e515-e516 (2015).
149. Qiu, Y. et al. Nucleoside diphosphate kinase B deficiency causes a diabetes-like vascular pathology via up-regulation of endothelial angiopoietin-2 in the retina. Acta Diabetol. 53, 81-89 (2016).
150. Rangasamy, S., Srinivasan, R., Maestas, J., McGuire, P. G. & Das, A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 52, 3784-3791 (2011).
151. Hammes, H. P. et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53, 1104-1110 (2004).
152. Ogura, S. et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. JCI Insight 2, e90905 (2017).
153. Cahoon, J. M. et al. Intravitreal AAV2. COMP-Ang1 prevents neurovascular degeneration in a murine model of diabetic retinopathy. Diabetes 64, 4247-4259 (2015).
154. Kather, J. N. et al. Angiopoietin-1 is regulated by miR-204 and contributes to corneal neovascularization in KLEIP-deficient mice. Invest. Ophthalmol. Vis. Sci. 55, 4295-4303 (2014).
155. Monk, B. J. et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 15, 799-808 (2014).
156. Monk, B. J. et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol. Oncol. 143, 27-34 (2016).
157. Campochiaro, P. A. et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 122, 545-554 (2015).
158. Campochiaro, P. A. et al. Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology 123, 1722-1730 (2016).
159. Salmon, A. H. et al. Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovasc. Res. 1, 24-33 (2009).
160. Kanakaraj, P. et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 4, 600-613 (2012).
161. Davis, S. et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 10, 38-44 (2003).
162. Kim, K. T. et al. Oligomerization and multimerization is critical for angiopoietin-1 to bind and phosphorylate Tie2. J. Biol. Chem. 280, 20126-20131 (2005).
163. Koblizek, T. I., Weiss, C., Yancopoulos, G. D., Deutsch, U. & Risau, W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8, 529-532 (1998).
164. Huang, J. et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int. J. Oncol. 34, 79-87 (2009).
165. Zhang, Z. G., Zhang, L., Croll, S. D. & Chopp, M. Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice. Neuroscience 113, 683-687 (2002).
166. Oh, N. et al. A designed angiopoietin-1 variant, dimeric CMP-Ang1 activates Tie2 and stimulates angiogenesis and vascular stabilization in N-glycan dependent manner. Sci. Rep. 5, 15291 (2015).
167. Cho, C. H. et al. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc. Natl Acad. Sci. USA 101, 5547-5552 (2004).
168. Alfieri, A. et al. Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis. Crit. Care 16, R182 (2012).
169. Ryu, J. K. et al. Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse. Sci. Rep. 5, 9222 (2015).
170. Jin, H. R. et al. Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse. Diabetes 60, 969-980 (2011).
171. Jung, Y. J. et al. The effects of designed angiopoietin-1 variant on lipid droplet diameter, vascular endothelial cell density and metabolic parameters in diabetic db/db mice. Biochem. Biophys. Res. Commun. 420, 498-504 (2012).
172. Sung, H. K. et al. COMP-angiopoietin-1 enhances skeletal muscle blood flow and insulin sensitivity in mice. Am. J. Physiol. Endocrinol. Metab. 297, E402-E409 (2009).
173. Cho, C. H. et al. Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 101, 5553-5558 (2004).
174. Kim, D. H. et al. COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. Kidney Int. 76, 1180-1191 (2009).
175. Kim, S. R. et al. Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury. Exp. Mol. Med. 40, 320-331 (2008).
176. Lee, S. W. et al. Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade. Mol. Med. 17, 1095-1106 (2011).
177. Youn, S. W. et al. COMP-Ang1 stimulates HIF-1α-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment. Blood 117, 4376-4386 (2011).
178. Shin, H. Y. et al. Protective role of COMP-Ang1 in ischemic rat brain. J. Neurosci. Res. 88, 1052-1063 (2010).
179. Jung, Y. J. et al. Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury. Am. J. Physiol. Renal Physiol. 297, F952-F960 (2009).
180. Byun, S. J. et al. Cartilage oligometric matrix protein-angiopoietin-1 promotes revascularization through increased survivin expression in dermal endothelial cells of skin grafts in mice. Am. J. Pathol. 171, 1682-1690 (2007).
181. Jeong, B. C. et al. COMP-Ang1, a chimeric form of angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation. Bone 46, 479-486 (2010).
182. Zhou, L. et al. COMP-angiopoietin1 potentiates the effects of bone morphogenic protein-2 on ischemic necrosis of the femoral head in rats. PLoS ONE 9, e110593 (2014).
183. Park, B. H. et al. COMP-angiopoietin-1 accelerates bone formation during distraction osteogenesis. Bone 46, 1442-1448 (2010).
184. Choi, H. et al. The angiopoietin-1 variant COMP-Ang1 enhances BMP2-induced bone regeneration with recruiting pericytes in critical sized calvarial defects. PLoS ONE 10, e0140502 (2015).
185. Anisimov, A. et al. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation 127, 424-434 (2013).
186. Herbst, R. S. et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 27, 3557-3565 (2009).
187. Monk, B. J. et al. Incidence and management of edema associated with trebananib (AMG 386). Gynecol. Oncol. 130, 636-641 (2013).
188. Atkins, M. B. et al. Trebananib (AMG 386) in combination with sunitinib in patients with metastatic renal cell cancer: an open-la-uppressed-enter, Phase II study. J. Clin. Oncol. 33, 3431-3438 (2015).
189. Kamba, T. et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560-H576 (2006).
190. Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788-1795 (2007).
191. Thomas, M. et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to pan-angiopoietin-1/-2 inhibitors. PLoS ONE 8, e54923 (2013).
192. Motzer, R. J. et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother. Pharmacol. 74, 739-750 (2014).
193. Veikkola, T. et al. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J. 17, 2006-2013 (2003)
194. Pemovska, T. et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519, 102-105 (2015).
195. Valenzuela, D. M. et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl Acad. Sci. USA 96, 1904-1909 (1999).
196. Kim, I. et al. Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3. FEBS Lett. 443, 353-356 (1999).
197. Nishimura, M. et al. Angiopoietin-3, a novel member of the angiopoietin family. FEBS Lett. 448, 254-256 (1999).
198. Abdulmalek, K. et al. Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L582-L590 (2001).
199. Yamakawa, M. et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res. 93, 664-673 (2003).
200. Yamakawa, M. et al. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am. J. Physiol. Renal Physiol. 287, F649-F657 (2004).
201. Lee, H. J. et al. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J. 18, 1200-1208 (2004).
202. Kwon, M. H. et al. Effect of intracavernous administration of angiopoietin-4 on erectile function in the streptozotocin-induced diabetic mouse. J. Sex. Med. 10, 2912-2927 (2013).
203. Soblet, J., Limaye, N., Uebelhoer, M., Boon, L. M. & Vikkula, M. Variable somatic TIE2 mutations in half of sporadic venous malformations. Mol. Syndromol. 4, 179-183 (2013).
204. Ye, C. et al. Somatic mutations in exon 17 of the TEK gene in vascular tumors and vascular malformations. J. Vasc. Surg. 54, 1760-1768 (2011).
205. Soblet, J. et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J. Invest. Dermatol. 137, 207-216 (2016).
206. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
207. Kang, H. C., Baek, S. T., Song, S. & Gleeson, J. G. Clinical and genetic aspects of the segmental overgrowth spectrum due to somatic mutations in PIK3CA. J. Pediatr. 167, 957-962 (2015).
208. Luks, V. L. et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J. Pediatr. 166, 1048-1054 (2015).
209. Osborn, A. J. et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum. Mol. Genet. 24, 926-938 (2015).
210. Vikkula, M. et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87, 1181-1190 (1996).
211. Winderlich, M. et al. VE-PTP controls blood vessel development by balancing Tie-2 activity. J. Cell Biol. 185, 657-671 (2009).
212. Nottebaum, A. F. et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF. J. Exp. Med. 205, 2929-2945 (2008).
213. Wessel, F. et al. Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin. Nat. Immunol. 15, 223-230 (2014).
214. Wouters, V. et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur. J. Hum. Genet. 18, 414-420 (2010).
215. Boscolo, E. et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J. Clin. Invest. 125, 3491-3504 (2015).
216. Natynki, M. et al. Common and specific effects of TIE2 mutations causing venous malformations. Hum. Mol. Genet. 24, 6374-6389 (2015).
217. Ubezio, B. et al. Synchronization of endothelial Dll4-Notch dynamics switch blood vessels from branching to expansion. eLIFE 5, e12167 (2016).
218. del Toro, R. et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116, 4025-4033 (2010).
219. Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000 (2002).
220. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. & McDonald, D. M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163, 1801-1815 (2003).
221. Hughes, D. P., Marron, M. B. & Brindle, N. P. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-κB inhibitor ABIN-2. Circ. Res. 92, 630-636 (2003).
222. Tadros, A., Hughes, D. P., Dunmore, B. J. & Brindle, N. P. ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1. Blood 102, 4407-4409 (2003).
223. Sako, K. et al. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. J. Biol. Chem. 284, 5592-5601 (2009).
224. Demolli, S. et al. MicroRNA-30 mediates anti-inflammatory effects of shear stress and KLF2 via repression of angiopoietin 2. J. Mol. Cell Cardiol. 88, 111-119 (2015).
225. Umeda, N. et al. Suppression and regression of choroidal neovascularization by systemic administration of an α5β1 integrin antagonist. Mol. Pharmacol. 69, 1820-1828 (2006).
226. Pietila, R. et al. Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses. J. Cell Sci. 125, 2212-2223 (2012).
227. Pfister, F. et al. Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 57, 2495-2502 (2008).
228. Chan, B. & Sukhatme, V. P. Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function. FEBS Lett. 583, 1023-1028 (2009).
229. Chan, B., Yuan, H. T., Ananth Karumanchi, S. & Sukhatme, V. P. Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules. Biochem. Biophys. Res. Commun. 371, 475-479 (2008).
230. Broermann, A. et al. Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. J. Exp. Med. 208, 2393-2401 (2011).
231. Park, D. Y. et al. Lymphatic regulator PROX1 determines Schlemm's canal integrity and identity. J. Clin. Invest. 124, 3960-3974 (2014).
232. Patel, J. I., Hykin, P. G., Gregor, Z. J., Boulton, M. & Cree, I. A. Angiopoietin concentrations in diabetic retinopathy. Br. J. Ophthalmol. 89, 480-483 (2005).
233. Sato, T., Shima, C. & Kusaka, S. Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity. Am. J. Ophthalmol. 151, 353-357 (2011).
234. Loukovaara, S. et al. Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment. Graefes Arch. Clin. Exp. Ophthalmol. 252, 881-888 (2014).
235. Lorbeer, R. et al. Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur. J. Heart Fail. 15, 1327-1334 (2013).
236. Ueda, N. et al. Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant 20, 1335-1340 (2014).
237. Poss, J. et al. Angiopoietin-2 in acute myocardial infarction complicated by cardiogenic shock-a biomarker substudy of the IABP-SHOCK II-Trial. Eur. J. Heart Fail. 17, 1152-1160 (2015).
238. Ganter, M. T. et al. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ann. Surg. 247, 320-326 (2008).
239. Mankhambo, L. A. et al. The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children. Crit. Care 14, R91 (2010).
240. Golledge, J. et al. Plasma angiopoietin-1 is lower after ischemic stroke and associated with major disability but not stroke incidence. Stroke 45, 1064-1068 (2014).
241. Fischer, M. et al. Angiopoietin-1 is associated with cerebral vasospasm and delayed cerebral ischemia in subarachnoid hemorrhage. BMC Neurol. 11, 59 (2011).
242. Wang, Y. et al. High Angiopoietin-1 levels predict a good functional outcome within 72 h of an aneurysmal subarachnoid hemorrhage: A prospective study from a single center. J. Neurol. Sci. 356, 72-76 (2015).
243. Westra, J. et al. Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatol. (Oxford) 50, 665-673 (2011).
244. Lopez-Mejias, R. et al. Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clin. Exp. Rheumatol 31, 761-766 (2013).
245. Gerlicz, Z., Dziankowska-Bartkowiak, B., Dziankowska-Zaborszczyk, E. & Sysa-Jedrzejowska, A. Disturbed balance between serum levels of receptor tyrosine kinases Tie-1, Tie-2 and angiopoietins in systemic sclerosis. Dermatology 228, 233-239 (2014).
246. Scholz, A. et al. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am. J. Gastroenterol. 102, 2471-2481 (2007).
247. Pauta, M. et al. Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver Int. 35, 1383-1392 (2015).
248. Hernandez-Bartolome, A. et al. Angiopoietin-2 serum levels improve noninvasive fibrosis staging in chronic hepatitis C: a fibrogenic-angiogenic link. PLoS ONE 8, e66143 (2013).
249. Liu, K. L. et al. Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit. Care 18, R100 (2014).
250. Tsai, Y. C. et al. Angiopoietin-2 as a prognostic biomarker of major adverse cardiovascular events and all-cause mortality in chronic kidney disease. PLoS ONE 10, e0135181 (2015).
251. Pappa, C. A. et al. Prognostic impact of angiopoietin-2 in multiple myeloma. J. Cancer Res. Clin. Oncol. 140, 1801-1805 (2014).
252. Bhaskar, A. et al. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk. Res. 37, 410-415 (2013).
253. Coelho, A. L. et al. Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC. PLoS ONE 9, e90009 (2014).
254. Makhoul, I. et al. High-circulating Tie2 is associated with pathologic complete response to chemotherapy and antiangiogenic therapy in breast cancer. Am. J. Clin. Oncol. 39, 248-254 (2014).
255. Li, P., He, Q., Luo, C. & Qian, L. Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer. Int. J. Clin. Exp. Pathol. 8, 660-664 (2015).
256. Jary, M. et al. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol. Biomarkers Prev. 24, 603-612 (2015).
257. Gayed, B. A. et al. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. BMC Urol. 15, 24 (2015).
258. Miyahara, K. et al. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br. J. Cancer 109, 2072-2078 (2013).
259. Maffei, R. et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 116, 584-592 (2010).
260. Hou, H. A. et al. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk. Res. 32, 904-912 (2008).
261. van de Weg, C. A. et al. Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers for plasma leakage in patients with acute dengue virus infection. J. Clin. Virol. 60, 328-335 (2014).
262. Zinter, M. S. et al. Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality. Am. J. Physiol. Lung Cell. Mol. Physiol. 310, L224-L231 (2016).
263. Luz Fiusa, M. M. et al. A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit. Care 17, R169 (2013).
264. Giuliano, J. S. Jr. et al. The temporal kinetics of circulating angiopoietin levels in children with sepsis. Pediatr. Crit. Care Med. 15, e1-e8 (2014).
265. Lymperopoulou, K. et al. Angiopoietin-2 associations with the underlying infection and sepsis severity. Cytokine 73, 163-168 (2015).
266. Kranidioti, H. et al. Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes. Immunol. Lett. 125, 65-71 (2009).
267. Giuliano, J. S. Jr. et al. Admission angiopoietin levels in children with septic shock. Shock 28, 650-654 (2007).
268. Orfanos, S. E. et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit. Care Med. 35, 199-206 (2007).
269. Lin, S. M. et al. Circulating angiopopietin-1 correlates with the clinical course of multiple organ dysfunction syndrome and mortality in patients with severe sepsis. Med. (Baltimore) 94, e878 (2015).
270. Fang, Y. et al. Prognostic significance of the angiopoietin-2/angiopoietin-1 and angiopoietin-1/Tie-2 ratios for early sepsis in an emergency department. Crit. Care 19, 367 (2015).
271. Calfee, C. S. et al. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit. Care Med. 40, 1731-1737 (2012).
272. Ong, T. et al. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit. Care Med. 38, 1845-1851 (2010).
273. Hadem, J. et al. Angiopoietin-2 in acute liver failure. Crit. Care Med. 40, 1499-1505 (2012).
274. Xie, Z. et al. Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood 119, 4321-4332 (2012).
275. Wada, T. et al. Using angiogenic factors and their soluble receptors to predict organ dysfunction in patients with disseminated intravascular coagulation associated with severe trauma. Crit. Care 16, R63 (2012).
276. Wada, T. et al. Angiogenic factors and their soluble receptors predict organ dysfunction and mortality in post-cardiac arrest syndrome. Crit. Care 16, R171 (2012).
277. Kumpers, P. et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med. 36, 462-470 (2010).
278. Buddingh, K. T. et al. Early angiopoietin-2 levels after onset predict the advent of severe pancreatitis, multiple organ failure, and infectious complications in patients with acute pancreatitis. J. Am. Coll. Surg. 218, 26-32 (2014).
279. Whitcomb, D. C. et al. Angiopoietin-2, a regulator of vascular permeability in inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United States and Germany. Am. J. Gastroenterol. 105, 2287-2292 (2010).
280. Prapansilp, P. et al. A clinicopathological correlation of the expression of the angiopoietin-Tie-2 receptor pathway in the brain of adults with Plasmodium falciparum malaria. Malar. J. 12, 50 (2013).
281. Brouwers, J. et al. Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers. PLoS ONE 8, e64850 (2014).
282. Conroy, A. L. et al. Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study. Crit. Care Med. 40, 952-959 (2012).
283. Jain, V. et al. Plasma levels of angiopoietin-1 and -2 predict cerebral malaria outcome in Central India. Malar. J. 10, 383 (2011).
284. Lukasz, A. et al. Angiopoietin-2 in adults with congenital heart disease and heart failure. PLoS ONE 8, e66861 (2013).
285. Poss, J. et al. Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin. Res. Cardiol. 104, 380-387 (2015).
286. Nikolakopoulou, S. et al. Serum angiopoietin-2 and CRP levels during COPD exacerbations. COPD 11, 46-51 (2014).
287. Koksal, B. T., Ozbek, O. Y., Bayraktar, N. & Yazici, A. C. Evaluation of angiopoietin 1 and 2, vascular endothelial growth factor, and tumor necrosis factor alpha levels in asthmatic children. Allergy Asthma Proc. 35, 482-488 (2014).
288. Makowska, J. S., Cieslak, M., Jarzebska, M., Lewandowska-Polak, A. & Kowalski, M. L. Angiopoietin-2 concentration in serum is associated with severe asthma phenotype. Allergy Asthma Clin. Immunol. 12, 8 (2016).
289. Lim, H. S., Blann, A. D., Chong, A. Y., Freestone, B. & Lip, G. Y. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 27, 2918-2924 (2004).
290. Li, L., Qian, L. & Yu, Z. Q. Serum angiopoietin-2 is associated with angiopathy in type 2 diabetes mellitus. J. Diabetes Complications 29, 568-571 (2015).
291. Feng, Y. et al. The absence of angiopoietin-2 leads to abnormal vascular maturation and persistent proliferative retinopathy. Thromb. Haemost. 102, 120-130 (2009).
292. Feng, Y. et al. Angiopoietin-2 deficiency decelerates age-dependent vascular changes in the mouse retina. Cell Physiol. Biochem. 21, 129-136 (2008).
293. Feng, Y. et al. Decreased hypoxia-induced neovascularization in angiopoietin-2 heterozygous knockout mouse through reduced MMP activity. Cell Physiol. Biochem. 23, 277-284 (2009).
294. Feng, Y. et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb. Haemost. 97, 99-108 (2007).
295. Pfister, F. et al. Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. Acta Diabetol. 47, 59-64 (2010).
296. Nambu, H. et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther. 11, 865-873 (2004).
297. Karlan, B. Y. et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 30, 362-371 (2012).
298. Hong, D. S. et al. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget 5, 11154-11167 (2014).
299. Papadopoulos, K. P. et al. A phase I first-in-human study of nesvacumab (REGN910), a fully-human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 22, 1348-1355 (2015).
300. Leow, C. C. et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int. J. Oncol. 40, 1321-1330 (2012).
301. Regula, J. T. et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol. Med. 381, 1265-1288 (2016).
302. Demetri, G. D. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 295-302 (2013).
303. Smith, B. D. et al. Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2. Mol. Cancer Ther. 14, 2023-2034 (2015).
304. Garcia-Manero, G. et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin. Cancer Res. 21, 985-994 (2015).
305. Koh, Y. J. et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18, 171-184 (2010).
306. Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl Med. 9, eaak9670 (2017).
307. Leppänen, V. M., Saharinen, P. & Alitalo, K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc. Natl Acad. Sci. USA 114, 4376-4381 (2017).
308. Moore, J. O., Lemmon, M. A. & Ferguson, K. M. Dimerization of Tie2 mediated by its membrane-proximal FNIII domains. Proc. Natl Acad. Sci. USA 114, 4382-4387 (2017).
309. Park, J. S. et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell 30, 953-967 (2016).
310. Brown, J. L. et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 9, 145-156 (2010).
311. Yu, X. et al. Structural basis for angiopoietin-1-mediated signaling initiation. Proc. Natl Acad. Sci. USA 110, 7205-7210 (2013).
312. Shewchuk, L. M. et al. Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure 8, 1105-1113 (2000).
313. Bocharov, E. V. et al. The conformation of the epidermal growth factor receptor transmembrane domain dimer dynamically adapts to the local membrane environment. Biochemistry 56, 1697-1705 (2017).